An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
Diabetes & Metabolism Journal
;
: 99-114, 2016.
Article
in English
| WPRIM
| ID: wpr-15202
ABSTRACT
Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogenesis. The two primary mechanisms of T2DM pathogenesis are pancreatic β-cell dysfunction and insulin resistance. Pancreatic β-cell dysfunction is recognized to be a prerequisite for the development of T2DM. Therapeutic modalities that improve β-cell function are considered critical to T2DM management; however, blood glucose control remains a challenge for many patients due to suboptimal treatment efficacy and the progressive nature of T2DM. Incretin-based therapies are now the most frequently prescribed antidiabetic drugs in Korea. Incretin-based therapies are a favorable class of drugs due to their ability to reduce blood glucose by targeting the incretin hormone system and, most notably, their potential to improve pancreatic β-cell function. This review outlines the current understanding of the incretin hormone system in T2DM and summarizes recent updates on the effect of incretin-based therapies on β-cell function and β-cell mass in animals and humans.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Blood Glucose
/
Insulin Resistance
/
Treatment Outcome
/
Diabetes Mellitus
/
Diabetes Mellitus, Type 2
/
Incretins
/
Hypoglycemic Agents
/
Korea
Limits:
Animals
/
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Diabetes & Metabolism Journal
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS